Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.22 USD
Change Today +0.16 / 1.99%
Volume 853.0K
BDSI On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

biodelivery sciences intl (BDSI) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/12/14 - $18.48
52 Week Low
04/30/15 - $7.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

biodelivery sciences intl (BDSI) Related Businessweek News

No Related Businessweek News Found

biodelivery sciences intl (BDSI) Details

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer marketed under the BREAKYL name in Europe and PAINKYL name in Taiwan; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA for the treatment of chronic pain. The company also develops Clonidine Topical Gel, which is in Phase III clinical trial to treat painful diabetic neuropathy and other indications; and buprenorphine depot injection. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Arcion Therapeutics, Inc.; Evonik Corporation; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

29 Employees
Last Reported Date: 03/16/15
Founded in 1997

biodelivery sciences intl (BDSI) Top Compensated Officers

Chief Executive Officer, President, Chief Sci...
Total Annual Compensation: $751.4K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $370.9K
Executive Vice President of Product Developme...
Total Annual Compensation: $434.2K
Compensation as of Fiscal Year 2014.

biodelivery sciences intl (BDSI) Key Developments

BioDelivery Sciences International, Inc. Appoints Sarah DeRossett as Vice President of Clinical Research and Medical Affairs

BioDelivery Sciences International, Inc. has appointed Sarah DeRossett, MD, PhD to the position of Vice President of Clinical Research and Medical Affairs. Dr. DeRossett joins BDSI with nearly twenty-five years of clinical and pharmaceutical industry experience in the neurosciences area. Dr. DeRossett will oversee clinical research activities for BDSI's products in development as well as the medical support for BDSI's currently marketed product, BUNAVAIL® (buprenorphine and naloxone) buccal film. Following more than 10 years as the Director of the Chronic Pain and Headache Clinic at Emory University School of Medicine and time in private practice, Dr. DeRossett joined GlaxoSmithKline in the neurosciences therapy area, where she was responsible for leading the clinical development of a number of compounds in a variety of areas including those for Alzheimer's disease, Parkinson's disease, epilepsy, restless leg syndrome and neuropathic pain.

BioDelivery Sciences International, Inc. - Special Call

To report results of the Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo.  In addition, a strong safety profile for the product was observed.  The results of this trial provide data that will allow the company to better refine the protocol criteria to capture a more 'enriched' patient population and target site selection.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDSI:US $8.22 USD +0.16

BDSI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Flamel Technologies SA $14.34 USD +0.46
PlasmaTech Biopharmaceuticals Inc $2.83 USD +0.02
Skyepharma PLC 278.00 GBp -22.00
XenoPort Inc $6.08 USD +0.15
Zogenix Inc $1.43 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation BDSI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODELIVERY SCIENCES INTL, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at